Skip to main content

Advertisement

SpringerLink
Log in

Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy

  • Gynecologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purpose

This study was designed to compare quality of life in a sample of Italian patients affected by platinum-sensitive recurrent ovarian cancer and submitted to chemotherapy alone or secondary cytoreductive surgery plus chemotherapy through validated questionnaires.

Methods

From January 2007 to December 2012, consecutive patients with suspicious recurrence of ovarian cancer, referred to the Division of Gynecologic Oncology at the University Campus Bio-Medico of Rome, were assessed for this prospective, case-control study. After a diagnostic laparoscopy, surgical resectable patients were enrolled in group A (surgery plus chemotherapy). Patients not suitable for optimal debulking surgery and all patients who refused surgery were enrolled in group B (chemotherapy alone). At beginning of treatment, after the third and sixth cycle of chemotherapy, all eligible patients were asked to fill in QLQ-C30 (version 3.0) and EORTC QLQ-OV28 questionnaires.

Results

Group A included 38 patients and underwent SCS followed by chemotherapy; group B included 16 patients that were submitted to chemotherapy alone. Quality-of-life scores of both questionnaires were comparable between groups, with the exception of constipation and pain, which resulted significantly worsened in Group A at 3 months. This difference was no longer present at 6 months. Median overall survival was 72 % for Group A and 56 % in Group B at median follow-up of 35 months for Group A and 32 months for Group B.

Conclusions

Both surgery followed by chemotherapy and chemotherapy alone seem to have a negligible impact on QOL. SCS plus chemotherapy seems to be an effective and tolerable therapeutic option in platinum-sensitive recurrences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. American Cancer Society. Cancer facts and figures 2013. Atlanta: American Cancer Society, 2013.

    Google Scholar 

  2. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.

    Article  PubMed  Google Scholar 

  3. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynecol Obstet. 2003;83(Suppl):135–66.

    Article  Google Scholar 

  4. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265–74.

    Article  PubMed  Google Scholar 

  5. Al Rawahi T, Lopes AD, Bristow RE. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;28:2.

    Google Scholar 

  6. Angioli R, Palaia I, Zullo MA, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol. 2006;100:455–61.

    Article  PubMed  Google Scholar 

  7. Dindo D, Dematrtines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and result of a survey. Ann Surg. 2004;240:205–13.

    Article  PubMed Central  PubMed  Google Scholar 

  8. World Health Organization. WHO handbook for reporting results of cancer treatment (offset publication no. 48). Geneva: World Health Organization; 1979:16–21.

    Google Scholar 

  9. Bjordal K, deGraeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (The EORTC QLQ-H&N35). Eur J Cancer. 2000;36:213–9.

    Article  Google Scholar 

  10. Greimel E, Bottomley A, Cull A, et al; EORTC Quality of Life Group and the Quality of Life Unit. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39:1402–8. Published correction appears in Eur J Cancer. 2003;39(17):2570.

  11. Scott NW, Fayers PM. The EORTC QLQ_C30 scoring manual. 3rd edn. Brussels: European Organisation for Research and Treatment of Cancer; 2001.

    Google Scholar 

  12. Gadducci A, Lacconi P, Cosio S, et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol. 2000;79(3):344–9.

    Article  CAS  PubMed  Google Scholar 

  13. Gungor M, Ortac F, Arvas M, et al. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol. 2005;97(1):74–9.

    Article  PubMed  Google Scholar 

  14. Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol. 2006;13(12):1702–10.

    Article  PubMed  Google Scholar 

  15. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004;95(2):273–80.

    Article  CAS  PubMed  Google Scholar 

  16. Santillan A, Karam AK, Li AJ, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol. 2007;104:686–90.

    Article  PubMed  Google Scholar 

  17. Tebes SJ, Sayer RA, Palmer JM, et al. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2007;106(3):482–7.

    Article  PubMed  Google Scholar 

  18. Galaal K, Naik R, Bristow RE, et al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2010; (6).

  19. Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:771–5.

    Article  PubMed  Google Scholar 

  20. Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21(4):750–5.

    Article  PubMed  Google Scholar 

  21. Cella D. What do global quality-of-life questions really measure? Insights from Hobday et al and the “do something” rule. J Clin Oncol. 2003;21(16): 3178–9.

    Article  PubMed  Google Scholar 

  22. WHO. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res. 1993;2(2):153–9.

    Article  Google Scholar 

  23. Angioli R, Plotti F, Aloisi A, et al. Does extensive upper abdomen surgery during primary cytoreduction impact on long-term quality of life? Int J Gynecol Cancer. 2013;23(3):442–7.

    Article  PubMed  Google Scholar 

  24. Angioli R, Plotti F, Cafà EV, et al. Quality of life in patients with endometrial cancer treated with or without systematic lymphadenectomy. Eur J Obstet Gynecol Reprod Biol. 2013;170(2):539–43.

    Article  PubMed  Google Scholar 

  25. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer. 1997;33:1025–30.

    Article  CAS  PubMed  Google Scholar 

  26. Eton D, Fairclough D, Cella D, et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003;21:1536–43.

    Article  PubMed  Google Scholar 

  27. Coates A, Gebski V, Signorini D, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer: Australian New Zealand Breast Cancer Trials Group. J Clin Oncol. 1992;10:1833–8.

    CAS  PubMed  Google Scholar 

  28. Dancey J, Zee B, Osoba D, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. Qual Life Res 1997;6:151–8.

    Article  CAS  PubMed  Google Scholar 

  29. Sugarbaker PH, Barofsky I, Rosenberg SA, et al. Quality of life assessment of patients in extremity sarcoma clinical trials. Surgery. 1982;91:17–23.

    CAS  PubMed  Google Scholar 

  30. Blazeby JM, Avery K, Sprangers M, et al. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol. 2006;24:3178–86.

    Article  PubMed  Google Scholar 

  31. Zamurovic M. Ovarian carcinoma patients–life quality analysis in the postoperative period. How to improve it? Eur J Gynaecol Oncol. 2010;31(6):672–4.

    CAS  PubMed  Google Scholar 

  32. Woelber L, Jung S, Eulenburg C, et al. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer. Eur J Surg Oncol. 2010;36:583–8.

    Article  CAS  PubMed  Google Scholar 

  33. Vernooij F, Heintz AP, Coebergh JW, et al. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol. 2009;112:455–61.

    Article  PubMed  Google Scholar 

  34. Bristow RE, Palis BE, Chi DS, et al. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010;118:262–7.

    Article  PubMed  Google Scholar 

  35. Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21:289–95.

    Article  PubMed  Google Scholar 

  36. Tian WJ, Chi DS, Sehouli J, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19:597–604.

    Article  PubMed  Google Scholar 

Download references

DISCLOSURE

All authors have nothing to disclosure.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Rome “Campus Bio-Medico”, Rome, Italy

    Francesco Plotti MD, Giuseppe Scaletta MD, Alessia Aloisi MD, Daniela Luvero MD, Stella Capriglione MD, Andrea Miranda MD, Roberto Montera MD, Carlo De Cicco Nardone MD, Corrado Terranova MD & Roberto Angioli MD

  2. University “Magna Graecia” of Catanzaro, Catanzaro, Italy

    Roberto Montera MD

Authors
  1. Francesco Plotti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Scaletta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessia Aloisi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniela Luvero MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stella Capriglione MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrea Miranda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roberto Montera MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carlo De Cicco Nardone MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Corrado Terranova MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Roberto Angioli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Scaletta MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Plotti, F., Scaletta, G., Aloisi, A. et al. Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy. Ann Surg Oncol 22, 2387–2394 (2015). https://doi.org/10.1245/s10434-014-4263-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-4263-8

Keywords

Search

Navigation